Do We All Look the Same Age?


Professor Rick Steeds Cardiologist, Queen Elizabeth Hospital, Birmingham UK



Delivering the best in care


Queen Elizabeth Hospital Birmingham






University of Birmingham






The City of Birmingham





A City of Leisure and Culture





Friendly Locals!






Delivering the best in care


Outline

- What abnormalities should you look out for?
- Current treatments
- The pathophysiology of cardiomyopathy in AS
- A different perspective...







12-Lead Electrocardiogram (EKG)




12-lead ECG is normal in 38-62% adults with AS




12-Lead Electrocardiogram (EKG)




The most common abnormality is T wave inversion in 21/47 (45%)




Echocardiography





Transthoracic echocardiography is normal in 36-62% adults with AS




Echocardiography







Most common abnormality is relaxation of the heart in 20/47 (43%)




Magnetic Resonance Imaging








Magnetic Resonance Imaging






enhancement in 21/47 (45%)



Delivering the best in care

Summary

- Cardiovascular disease not affect everyone with AS
- Standard tests picks up abnormalities in @ one third





Standard Therapies in AS Cardiovascular Disease

No specific therapy for AS cardiomyopathy

STAGE A: At-Risk for Heart Failure	STAGE B: Pre-Heart Failure		STAGE C: Symptomatic Heart Failure		STAGE D: Advanced Heart Failure	
Patients at risk for HF but	Patients without current or	•		•	Marked HF symptoms	
without current or previous symptoms/signs of HF and without structural/ functional heart disease or abnormal biomarkers	previous symptoms/signs of HF but evidence of 1 of the following:		Patients with current or previous symptoms/signs of HF		that interfere with daily life and with recurrent hospitalizations despite	
	Structural heart disease Evidence of increased				attempts to optimize GDMT	
Patients with hypertension, CVD, diabetes, obesity,	filling pressures Risk factors and					
exposure to cardiotoxic agents, genetic variant for cardiomyopathy, or family	 increased natriuretic peptide levels or persistently elevated 					
history of cardiomyopathy	cardiac troponin in the absence of competing diagnoses					

Risk factors: abnormal NTproBNP (49%) and HS Tn (34%) in AS



Delivering the best in care

Heidenreich Circulation 2022


Determinants of Therapy

Type of HF		HFrEF	HFmrEF	HFpEF	
CRITERIA	1	Symptoms ± Signs ^a	Symptoms ± Signs ^a	Symptoms ± Signs ^a	
	2	LVEF ≤40%	LVEF 41- 49% ^b	LVEF ≥50%	
	3	-	-	Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures, including raised natriuretic peptides ^c	
A 3 225 225 225 225 225 225 225 225 225 22	1300	Death at 1 Year		B 2 Death/Hospitalization at 1 Year B 19 B 19	

Delivering the best in care

Kociol Circ HF 2011

Standard Evidence-Based Therapy for HFrEF





Consider restricting dietary sodium; no proven benefit vitamins, iron, thiamine

Delivering the best in care


McDonagh EHJ 2021

Response to Therapy






B Hospitalization for Heart Failure




C Death from Cardiovascular Causes



Delivering the best in care

McMurray NEJM 2019

Standard Evidence-Based Therapy for HFpEF





0


Delivering the best in care

Heidenreich Circulation 2022

Circulatory Support and Transplant









Summary

- Cardiovascular disease not affect everyone with AS
- Standard tests picks up abnormalities in @ one third
- There is no specific therapy to AS cardiomyopathy but current standard therapies are available and help
- These are not curative and there is residual risk to impaired quality of life and life expectancy






The Myocardium



'Collagen fibres between the cardiac muscle fibres, some of which are enlarged'






Delivering the **best** in care

Marshall Arch Intern Med 2005

Variation in Cardiac Fibrosis



Normal


Interstitial



Delivering the best in care

Frangiogiannis Cardiovasc Res 2021

Ageing and Cardiac Fibrosis




Common feature of ageing is progressive increase in collagen density and thickness

Delivering the best in care

Debessa Mech Ageing Dev 2001

Role of ALMS1

- ALMS1 is a component of the centrosome, organizing microtubules and providing structure to cells.
- Proposed role of *ALMS1* in cell cycle arrest of cardiomyocytes
- Dysregulation of the cell cycle to cell senescence, and often progressive with age.






Delivering the best in care

Slide courtesy Leena Patel

Phenoage and Chronological Age



Phenoage is a reliable measure of biological ageing that outperforms other measures for all-cause mortality, risk of cancer, healthspan, physical functioning, dementia




Levine Ageing 2018



Phenoage and AS

- 45 participants with AS
- Median phenoage 48yrs (IQR 35-72) cf median chronological age 29yrs (IQR 22-39)
- Phenoage older in 85%
- Median difference +18 yrs
- Looked at echo findings over 10 yrs: gradual ↓ LV size, ↑ wall thickness, ↓ GLS, ↑ E/A





Delivering the best in care


Patel Geroscience 2023

Summary

- Cardiovascular disease not affect everyone with AS
- Standard tests picks up abnormalities in @ one third
- There is no specific therapy to AS cardiomyopathy but current standard therapies are available and help
- These are not curative and there is residual risk to impaired quality of life and life expectancy
- Fibrosis is a core feature of pathogenesis of AS cardiomyopathy on PM and imaging
- Phenoage is advanced in AS does this offer insights?



The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study




Delivering the best in care

Lear Lancet 2017

Counting Your Steps...


This systemic review and meta-analysis of 12 cohorts including 111,309 individuals from the general population identified minimal and optimum step count targets for reducing adverse health outcomes.



Delivering the best in care

Stens JACC 2023


Tip 1: Exercise Reduces Your Biological Age



Delivering the best in care

Duggal Nature Reviews Imm 2019

Tip 2: Diet reduces Your Biological Age




10-50% reduced CI Intermittent fasting: - 5:2 diet Time limited to 4-12hrs Specific nutrients: - Protein? Increase – Methionine Microbiota: Mixed intake Vegetable and fruits

Delivering the best in care

Fontana Cell 2015

A Combination?



Tip 3: Do NOT Smoke

Smoker!





Delivering the **best** in care

Okada Plastic and Recon Surg 2013

Tip 3: Do NOT Smoke

Smoker!





Delivering the **best** in care

Okada Plastic and Recon Surg 2013


Tip 3: Do NOT Smoke

Smoker!

Smoker!



But 14 years longer!



Okada Plastic and Recon Surg 2013

Tip 4: Take Care with Alchohol


- Telomere length is a potential biomarker of ageing
- Repetitive nucleotide sequences act as cap at ends of chromosomes but 50-100 lost at each cell division
- Telomere shortening therefore occurs with cell ageing

Alcohol.intake.weekly	N			Estimate	LCI	UCI	p.value
Never drinker	8240		↓ ● 1	0.02	-0.003	0.043	0.081
Previous drinker	9393		⊢ ●⊷	-0.011	-0.033	0.011	0.332
<6 units	42279			0	0	0	0
6- <11 units	43536		H e H	0.003	-0.009	0.016	0.598
11- <17 units	46237		H ¢ H	0	-0.012	0.013	0.948
17- <29 units	48291		⊷	-0.014	-0.027	-0.001	0.034
29+ units	47378	,	● -	-0.046	-0.059	-0.032	2.36e-11
Alcohol use disorder	1301	·•		-0.146	-0.199	-0.093	6.14e-08
		-0.2 -0.1	0.0	0.1			
		Shorter telomeres	Longer telom	eres			

Delivering the best in care

Topiwala *Mol Psychiatry* 2022

Tip 5: Ideally Do It ALL!



Life expectancy at 45yrs in the healthiest was 3° 7.6yrs and 6.5yrs 2° more Healthiest: - >150mins/week - \ge 5 fruit and/or veg/day

- Non-smoker
- Alcohol <14U/week</p>
- Co-morbidity included:
 - Hypertension
 - Diabetes

Delivering the **best** in care


Chudusama PLOS Medicine 2020

Potential Factors









Summary

- Cardiovascular disease not affect everyone with AS
- Standard tests picks up abnormalities in @ one third
- There is no specific therapy to AS cardiomyopathy, but current standard therapies are available and help
- These are not curative and there is residual risk to impaired quality of life and life expectancy
- Fibrosis is a core feature of pathogenesis of AS cardiomyopathy on PM and imaging
- Phenoage is advanced in AS does this offer insights?
- Biological ageing can be modified: people with AS can do things that help

